Table 1.
Genre | Naming | Organic linker | Pore size (Å) | Drug loading | Ref. |
---|---|---|---|---|---|
Fe-MOFs | MIL-89 (Fe) | Muconic acid | 11 | Ibuprofen, azidothymidine triphosphate | 57 |
MIL-88A (Fe) | Fumaric acid | 6 | Ibuprofen, cidofovir | 57 | |
MIL-100 (Fe) | 1,3,5-Benzenetricarboxylic acid | 25, 29 | Gemcitabine-monophosphate, topotecan, isoniazid, doxycycline, tetracycline, docetaxel, azidothymidine triphosphate, lamivudine triphosphate | 57,62,68,70‒72 | |
MIL-101_NH2 (Fe) | Amino 1,4-benzenedicarboxylic acid | 29, 34 | Azidothymidine triphosphate, cidofovir, ethoxysuccinato-cisplatin | 57,73 | |
MIL-53 (Fe) | 1,4-Benzenedicarboxylic acid | 8.6 | Ibuprofen, oridonin | 50,63 | |
MIL-101 (Fe) | 2-Amino 1,4-benzenedicarboxylic acid | 25–30 | Ibuprofen, azidothymidine triphosphate | 57 | |
MIL-127 | 3,3ʹ,5,5ʹ-Azobenzenetetracarboxylate | 4 | Caffeine | 74 | |
Zn-MOFs | Zn (TATAT)2/3 ·3DMF·H2O | TATAT = 5,5ʹ,5ʹʹ-(1,3,5-Triazine-2,4,6-triyl) Tris (azanediyl)triisophthalate | 17, 21 | 5-Fluorouracil | 75 |
ZnBDP_X | 1,4-Bis(1H-pyrazol-4-yl)-2-X-benzene (H2BDP_X; X = H, NO2, NH2, OH) | 11 | Mitoxantrone | 64 | |
Bio-MOFs | Azobenzene-4,4ʹ-dicarboxylic acid and biphenyl-4,4ʹ-dicarboxylic acid | 8.3–26 | Etilefrine hydrochloride | 76 | |
Zn8(O)2(CDDB)6 (DMF)4(H2O) | 4,4ʹ-(9-H-Carbazole-3,6-diyl) dibenzoic acid | 28.1 × 23.17 | 5-Fluorouracil | 65 | |
ZIF-8 | 2-Methylimidazolate | 11.6 | 5-Fluorouracil, doxorubicin | 77,78 | |
Zr-MOFs | UiO-66 | 1,4-Benzenedicarboxylic acid | 8 | Caffeine, dichloroacetate | 53,74 |
UiO NMOFs | Amino-triphenyldicarboxylic acid | – | Cisplatin prodrug, siRNAs | 79 | |
UiO-66-NH2/NO2 | 1,4-Benzenedicarboxylic acid | – | Ketoprofen | 66 | |
K-MOFs | CD-MOF-1 | Cyclodextrins | 4–17 | Lansoprazole, azilsartan, budesonide, valsartan | 20,67,68,80 |
Cu-MOFs | HKUST-1 | 1,3,5-Benzenetricarboxylic acid | 14.67 | Ibuprofen | 69 |
MOF-2/MOF-3 | 1,3,5-Benzenetricarboxylic acid and isophthalic acid | 21.2/20.9 | Ibuprofen, doxorubicin hydrochloride | 69 |
‒, not applicable.